Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
20 results
- D1.532 - Phenotypic and Functional Comparison of LAD2, HMC-1.2, and Primary Human Mast Cells
- D1.529 - Evaluating the Disease-Modifying Potential of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis: An Update on the Pivotal HARBOR Study
- D1.530 - Patient Experience of Most Burdensome Nonadvanced Systemic Mastocytosis Symptoms From the Pivotal Summit Trial of Bezuclastinib
- D1.531 - Avapritinib in Indolent Systemic Mastocytosis: Real-world Data from a Greek Case Series
- D1.533 - Systemic mastocytosis despite normal baseline tryptase: a diagnostic pitfall in recurrent life-threatening anaphylaxis
D2.19 - Can Drug Provocation Be Avoided in Low-Risk Quinolone Reactions?
D2.25 - Epicutaneous responses to Bradykinin Receptor 1 and 2 agonists, Histamine, and mast cell agonists in Angiotensin Converting Enzyme Inhibitor angioedema
D2.17 - Diagnostic profitability of penicilloyl-polylysine and minor determinant mixture in urgent/preferred beta-lactam allergy studies in hospitalized patients from january 2023 to december 2025
D2.18 - Evaluating the Penicillin Allergy Diagnosis Process with Real-Life Data
D2.20 - Selective Fixed Drug Eruption from Etoricoxib with Safe Celecoxib Use: Role of Patch Testing
D2.21 - The Cyto-LTT: A multiplex cytokine assay to detect and assess the strength of T cell reactivity in drug hypersensitivity
D2.26 - Applying a phenotype-driven diagnostic algorithm to suspected hypersensitivity reactions to biologicals: a real-world experience
D2.27 - “Chronic Urticaria Following Dental Filling Procedure: A Clinical Evaluation”
D2.28 - When Cross-Reactivity Is Not the Answer: Immediate Multiple Drug Hypersensitivity to Aminopenicillins and Ceftriaxone
D2.29 - Use and knowledge of Phadiatop Infant and Fx5 in children from a primary care healthcare area
- D3.540 - Sources of IL-13 in Acute Versus Chronic Models of Eosinophilic Esophagitis
- D3.538 - Aeroallergen sensitisation as a risk factor for paediatric eosinophilic esophagitis
- D3.539 - Evaluation of Treatment Selection and Response in Patients with Eosinophilic Esophagitis Based on Clinical Findings and Allergy Testing
- D3.541 - Who takes the patient with eosinophilic esophagitis (EoE) and acute laryngeal edema?
- D3.542 - Prevalence of sensitization to panallergens and IgG4 profiles against specific foods in patients with allergic-phenotype eosinophilic esophagitis
Download the app
The congress at your fingertips
Available on
Download